Showing results (581-590 of 590) with videos related to
Sort By:
Pageof 59
You have reached the last page of results.This site can display upto 590 results.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.Cancer Research Communications|May 10, 2024
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy ResponseRobert J Norgard, Pratha Budhani, Sarah A O'Brien, et al.Journal of Medicinal Chemistry|February 26, 2016
Structure-Based Design of an in Vivo Active Selective BRD9 InhibitorLaetitia J Martin, Manfred Koegl, Gerd Bader, et al.The EMBO Journal|June 17, 2010
CIN85 regulates dopamine receptor endocytosis and governs behaviour in miceNoriaki Shimokawa, Kaisa Haglund, Sabine M Hölter, et al.Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.Annals of Anatomy = Anatomischer Anzeiger : Official Organ of the Anatomische Gesellschaft|November 6, 2018
Recommendations of the working group of the Anatomische Gesellschaft on reduction of formaldehyde exposure in anatomical curricula and institutesJens Waschke, Martin Bergmann, Lars Bräuer, et al.Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.Pageof 59